JB Chemicals & Pharmaceuticals

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Gross margins stood at 67.1 per cent for Q3FY25 and 66.5 per cent for 9M FY25

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

JB Pharma is on track to deliver strong results in the second half of financial year 2024-25

The company stated it has a strong order book for the remaining quarters of this financial year

Deliberations about the stake purchase are ongoing and no final decisions have been made, the people said. Other bidders may still remain interested in acquiring the stake, the people said

Company crosses Rs 1,000 crore quarterly revenue mark

JB Chemicals & Pharmaceuticals on Thursday said its net profit increased 25 per cent year-on-year to Rs 177 crore in the first quarter ended June 30, 2024. The drug firm had reported a net profit of Rs 142 crore in the April-June period last fiscal. Total income increased to Rs 1,010 crore in the June quarter from Rs 902 crore in the year-ago period, JB Pharma said in a regulatory filing. "Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin," CEO and Wholetime Director Nikhil Chopra stated. Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth, he added. "We expect the international business including CDMO business to pick up in the second half of the financial year. The good start .

JB Chemical's price has surpassed the crucial triple top resistance placed in the range of Rs 1,920-1,930. Stock has broken out from broken out from the consolidation, which held for last four months.

JB Pharma plans to maintain its presence in cardiology, focusing on hypertension, heart failure, and lipid-lowering treatments

The US private equity firm is looking to hire financial advisers to help evaluate a sale of its 53.8% stake in the Mumbai-based company, the people said

"We are growing at 16 per cent, compared to the Indian Pharma Market (IPM) growth of 8 per cent, and a 12 per cent growth of the market which we cover," Chopra said

JB Chemicals & Pharmaceuticals on Tuesday said its net profit rose 26 per cent to Rs 134 crore for the third quarter ended December 2023. The company reported a net profit of Rs 106 crore in the October-December period of the last fiscal. Revenue increased to Rs 845 crore in the third quarter compared to Rs 793 crore in the year-ago period, JB Pharma said in a statement. "Our focus on growing the domestic business ahead of the market continues, as reflected in the Q3 performance. The business once again stands out in this quarter," JB Pharma CEO and Wholetime Director Nikhil Chopra stated. In the international division, the formulations business is stable, he added. "Our approach to develop progressive portfolios is on track, resulting in a positive impact for the exports branded generics business," Chopra said. Shares of the company settled 1.18 per cent higher at Rs 1,724 apiece on the BSE.

JB Chemicals and Pharmaceuticals shall offer employment to the impacted associates working on this portfolio, it said today. JB Chemicals shares ended on BSE at Rs 1466 apiece, down marginally

JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 35 per cent increase in profit after tax at Rs 142 crore in the first quarter ended June 30, 2023. The company had posted a Profit After Tax (PAT) of Rs 105 crore in the same quarter last fiscal, JB Chemicals & Pharmaceuticals (JB Pharma) said in a statement. Revenue in the quarter under review stood at Rs 896 crore as against Rs 785 crore in the year-ago period, a growth of 14 per cent, it added. Domestic formulations business stood at Rs 489 crore, a growth of 17 per cent. Revenue from international business crossed the Rs 400 crore mark for the first time in a quarter, the company said. "Our domestic business continued its growth trajectory through strong momentum in our chronic portfolio and acquired assets. Our big brands, especially in the chronic segment, continue to outpace the market and have reached new milestones," JB Pharma CEO and Whole Time Director Nikhil Chopra said. The CDMO (Contract Development and ..

Stock to Watch on Tuesday, May 9: Canara Bank's net profit rose 90.6 per cent year-on-year (YoY) at Rs 3,175 crore in Q4FY23

A final decision on this will be taken during the board meeting to be held on 24 May 2023

JB Chemicals & Pharmaceuticals has reported 13 per cent rise in profit after tax at Rs 111 crore for the second quarter ended September 30, 2022. The drug firm had logged a profit after tax (PAT) of Rs 98 crore in July-September period of previous fiscal year. Revenue rose to Rs 809 crore in the period under review as compared with Rs 593 crore in the year-ago quarter, it said in a statement. "Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquired brands which have seamlessly transitioned in a short period," company CEO and Wholetime Director Nikhil Chopra said. The momentum in the international business continued across markets, with all three of the company's verticals performing well, he added. "Our strategic focus on key brands, segments and geographies is resulting in a consistent, sustained revenue growth. "And this growth, along with ...

Among individual stocks, the technical analyst recommends buying JK Tyre and J.B.Chemicals & Pharma.